Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients
Pediatric Blood & Cancer,

Yancey A et al. – Gender and cumulative dose are important clinical biomarkers of cisplatin ototoxicity. Severity of ototoxicity may be inversely related to age at time of exposure, with very young patients exhibiting higher grades of hearing loss following cisplatin therapy.

Methods
  • The authors performed a retrospective chart review of 102 pediatric patients who had completed cisplatin therapy for osteosarcoma, neuroblastoma, hepatoblastoma, or germ cell tumor.
  • Patients were diagnosed at Riley Hospital for Children between January 1995 and June 2008, were less than 18 years old at diagnosis, and had normal hearing prior to therapy.
  • Audiograms were scored using the Brock scale (0–4), a validated grading system for cisplatin-related hearing loss.

Results
  • Forty-two percent of the patients experienced hearing loss and 28% had moderate to severe ototoxicity (Brock score ≥2).
  • Males were at significantly greater risk for developing hearing loss than were females (P = 0.005, OR 4.812).
  • Age at cancer diagnosis was inversely related to severity of ototoxicity.
  • Patients who suffered Brock grade 3 ototoxicity had a mean age of 4.5 years versus 11.5 years and 7.2 years for grades 1 and 2, respectively (P = 0.02).
  • Cumulative cisplatin dose was also identified as a risk factor for development of ototoxicity (P = 0.03).

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Psychiatry

See All >> Messages include industry-sponsored communications and special communications from MDLinx

<

Most Popular Psychiatry Articles

1 Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: Outcome after long-term follow-up Psychiatry Research, December 3, 2014    Clinical Article

2 Are antidepressants equally effective in the long-term treatment of major depressive disorder? Human Psychopharmacology: Clinical and Experimental, December 8, 2014    Clinical Article

3 Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: An integrated analysis of 15 clinical trials Journal of Psychopharmacology, December 2, 2014    Clinical Article

4 Venlafaxine versus applied relaxation for generalized anxiety disorder: A randomized controlled study on clinical and electrophysiological outcomes Psychiatric Quarterly, December 19, 2014    Clinical Article

5 Nitrous oxide for treatment-resistant major depression: A proof-of-concept trial Biological Psychiatry, December 24, 2014    Clinical Article

6 Weight gain and associated factors in patients using newer antidepressant drugs General Hospital Psychiatry, December 4, 2014    Clinical Article

7 Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: A randomized, double-blind, placebo-controlled trial International Clinical Psychopharmacology, December 23, 2014    Clinical Article

8 Zolpidem and the risk of Parkinson's disease: A nationwide population-based study Journal of Psychiatric Research, August 1, 2014    Clinical Article

9 Rational-emotive and cognitive-behavior therapy (REBT/CBT) versus pharmacotherapy versus REBT/CBT plus pharmacotherapy in the treatment of major depressive disorder in youth: A randomized clinical trial Psychiatry Research, December 15, 2014    Clinical Article

10 Theta-burst stimulation: A new form of TMS treatment for depression? Depression and Anxiety, December 22, 2014    Clinical Article

11 The impact of telephone versus e-mail therapist guidance on treatment outcomes, therapeutic alliance and treatment engagement in Internet-delivered CBT for depression: A randomised pilot trial Internet Interventions, December 12, 2014    Clinical Article

12 Maternal thyroid autoantibody and elevated risk of autism in a national birth cohort Progress in Neuro-Psychopharmacology and Biological Psychiatry, December 1, 2014    Clinical Article

13 Living SMART — A randomized controlled trial of a guided online course teaching adults with ADHD or sub-clinical ADHD to use smartphones to structure their everyday life Internet Interventions, December 5, 2014    Clinical Article

14 Antipsychotic treatment and mortality in schizophrenia Schizophrenia Bulletin, December 16, 2014    Clinical Article

15 Blood manganese levels in relation to comorbid behavioral and emotional problems in children with attention-deficit/hyperactivity disorder Psychiatry Research, November 4, 2014    Clinical Article

16 Aripiprazole versus quetiapine in treatment-resistant obsessive–compulsive disorder: A double-blind clinical trial Therapeutic Advances in Psychopharmacology, December 24, 2014    Clinical Article
Exclusive Author Commentary

17 Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials JAMA Psychiatry, October 22, 2014    Evidence Based Medicine    Clinical Article

18 Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder JAMA Psychiatry, December 11, 2014    Evidence Based Medicine    Clinical Article

19 Cognitive effects of statin medications CNS Drugs, February 18, 2014    Clinical Article

20 Low serum levels of vitamin D are associated with post-stroke depression European Journal of Neurology, December 9, 2014    Clinical Article

Indexed Journals in Psychiatry : Current Psychiatry, Bipolar Disorders, American Journal of Psychiatry, Addictionmore

 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List